Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients - PubMed (original) (raw)

Comparative Study

Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients

A Gottsäter et al. Diabetes Care. 1993 Jun.

Abstract

Objective: To determine the effects of islet cell antibodies on beta-cell function during the first 3 yr after diagnosis in type II diabetic patients.

Research design and methods: beta-cell function in type II diabetic patients with (n = 11, 50 +/- 5 yr of age) and without (n = 10, 52 +/- 4 yr of age) ICA was followed prospectively and compared with beta-cell function in type I adult diabetic patients (n = 17, 37 +/- 5 yr of age) and in healthy control subjects (n = 34, age 45 +/- 3 yr). beta-cell function was evaluated as fasting C-peptide, 1 + 3 min C-peptide after intravenous glucose, and delta C-peptide after glucagon.

Results: Fasting C-peptide was equal in type II diabetic patients with ICA (0.30 +/- 0.03 nM) and type I diabetic patients (0.24 +/- 0.03 nM) at diagnosis, and decreased (P < 0.05) during 3 yr in these groups but not in type II diabetic patients without ICA. At diagnosis, type II diabetic patients with ICA showed a 1 + 3 min C-peptide (0.92 +/- 0.17 nM) lower (P < 0.001) than control subjects but higher (P < 0.05) than type I diabetic patients (0.53 +/- 0.11 nM). After 1 yr, 1 + 3 min C-peptide in type II diabetic patients with ICA had decreased (P < 0.05) to 0.18 +/- 0.11 nM and was equal to type I diabetic patients (0.38 +/- 0.10 nM). delta C-peptide after glucagon was equally impaired in type II diabetic patients with ICA (0.38 +/- 0.06 nM) and type I diabetic patients (0.35 +/- 0.11 nM) at diagnosis. After 3 yr, type II diabetic patients with ICA had fasting C-peptide of 0.09 +/- 0.04 nM, 1 + 3 min C-peptide of 0.18 +/- 0.10 nM, and delta C-peptide after glucagon of 0.20 +/- 0.09 nM, values equal to type I diabetic patients but lower (P < 0.01) than in type II diabetic patients without ICA, whose values remained unchanged; fasting C-peptide of 0.97 +/- 0.17 nM, 1 + 3 min C-peptide of 2.31 +/- 0.50 nM, and delta C-peptide after glucagon of 1.76 +/- 0.28 nM.

Conclusions: In patients considered type II diabetic with ICA, beta-cell function progressively decreased after diagnosis, and after 3 yr was similar to type I diabetic patients, whereas beta-cell function in type II diabetic patients without ICA was unchanged.

PubMed Disclaimer

Cited by

Low rate of latent autoimmune diabetes in adults (LADA) in patients followed for type 2 diabetes: A single center's experience in Turkey.
Tam AA, Ozdemir D, Bestepe N, Dellal FD, Bilginer MC, Faki S, Bicer C, Ersoy R, Cakir B. Tam AA, et al. Arch Endocrinol Metab. 2021 May 18;64(5):584-590. doi: 10.20945/2359-3997000000268. Arch Endocrinol Metab. 2021. PMID: 34033299 Free PMC article.
Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia.
Hope SV, Knight BA, Shields BM, Hill AV, Choudhary P, Strain WD, McDonald TJ, Jones AG. Hope SV, et al. Diabetologia. 2018 Jan;61(1):66-74. doi: 10.1007/s00125-017-4449-2. Epub 2017 Oct 5. Diabetologia. 2018. PMID: 28983693 Free PMC article.
Six-year follow-up of pancreatic beta cell function in adults with latent autoimmune diabetes.
Yang L, Zhou ZG, Huang G, Ouyang LL, Li X, Yan X. Yang L, et al. World J Gastroenterol. 2005 May 21;11(19):2900-5. doi: 10.3748/wjg.v11.i19.2900. World J Gastroenterol. 2005. PMID: 15902725 Free PMC article.
Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C.
Wesche B, Jaeckel E, Trautwein C, Wedemeyer H, Falorni A, Frank H, von zur Mühlen A, Manns MP, Brabant G. Wesche B, et al. Gut. 2001 Mar;48(3):378-83. doi: 10.1136/gut.48.3.378. Gut. 2001. PMID: 11171829 Free PMC article.
Diabetes in adolescent patients: diagnostic dilemmas.
Bricker LA, Draznin MB, Hare JD, Greydanus DE. Bricker LA, et al. Indian J Pediatr. 2001 Mar;68(3):223-7. doi: 10.1007/BF02723193. Indian J Pediatr. 2001. PMID: 11338217

Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients - PubMed (original) (raw)